Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.898
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: The Combination of Idelalisib and Rituximab

Postdoc journal
2014English

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Five Years of Experience With Rituximab Plus High-Dose Dexamethasone for Relapsed/Refractory Chronic Lymphocytic Leukemia

Archives of Medical Science
Medicine
2016English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparative Efficacy of Chronic Lymphocytic Leukemia Treatment With or Without Rituximab

Oncogematologiya
OncologyHematology
2019English

Rituximab in Combination With High-Dose Methylprednisolone for the Treatment of Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy